Back to top
more

Dipexium Pharmaceuticals, Inc. (DPRX)

(Delayed Data from NSDQ)

$1.34 USD

1.34
144,261

+0.04 (2.92%)

Updated Apr 19, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

PLx Pharma, Inc. [DPRX]

Reports for Purchase

Showing records 1 - 20 ( 22 total )

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 1

03/10/2017

Company Report

Pages: 5

We are dropping coverage of Dipexium Pharmaceuticals due to reallocation of resources

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 10.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 2

11/11/2016

Company Report

Pages: 7

Q3 results inline, no update on plans, maintain HOLD and $2.00 price target

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 3

10/25/2016

Company Report

Pages: 6

Phase 3 trials fail to meet primary and secondary endpoints, price target to $2.00

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 4

09/15/2016

Company Report

Pages: 8

Phase 3 data imminent, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 5

08/04/2016

Company Report

Pages: 8

Waiting on data, market size could be larger than our model, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 6

07/05/2016

Daily Note

Pages: 6

2H:2016 Top Ideas

Provider: Feltl & Company

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 7

05/12/2016

Company Report

Pages: 8

One patient left to enroll, Q1 expenses slightly higher, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 8

03/24/2016

Company Report

Pages: 8

Enrollment at ~86%, Q4 R-D higher than anticipated, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 9

01/04/2016

Daily Note

Pages: 6

2016 Top Ideas

Provider: Feltl & Company

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 10

11/19/2015

Company Report

Pages: 8

Enrollment at ~62%, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 11

08/13/2015

Company Report

Pages: 8

Trial enrollment beginning to accelerate, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 12

07/13/2015

Daily Note

Pages: 6

2H:2015 Top Ideas

Provider: Feltl & Company

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 13

06/03/2015

Company Report

Pages: 8

No European Trial required for Locilex approval; raising price target to $32.50

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 14

05/15/2015

Company Report

Pages: 8

On pace for Phase 3 top-line data in 2H15, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 15

03/24/2015

Company Report

Pages: 9

Q4 results ahead of expectations, trial sites increasing, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 16

01/05/2015

Daily Note

Pages: 7

2015 Top Ideas.

Provider: Feltl & Company

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 17

12/10/2014

Company Report

Pages: 9

EU approval with no European trials? Cubist acquisition and Executive Order

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 18

11/13/2014

Company Report

Pages: 8

Reported Q3, reiterate STRONG BUY, $21.75 price target

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 19

09/09/2014

Company Report

Pages: 10

ICAAC poster demonstrates broad activity for Locilex, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: PLx Pharma, Inc.

Industry: Medical - Drugs

Record: 20

08/13/2014

Company Report

Pages: 8

Reports Q2, reiterate STRONG BUY, $21.75 PT

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party
// eof